Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as
 ICB have changed the standard treatments of several metastatic tumor types. However, the
 response rate to ICB is low, and the biological bases for this response heterogeneity are
 poorly understood.

 In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB
 n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from
 patients with locally advanced or metastatic cancer, treated with ICB, in order to determine
 if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines)
 predicts response to these immunotherapies.
Inclusion Criteria:

 -  Age > 18 years

 -  Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with
 Immune check blockade

 -  Signed informed consent

 -  Affiliated to(or beneficiary of) the French Social Security

 Exclusion Criteria:

 -  Pregnant or breastfeeding woman or woman who does not apply effective contraception

 -  Emergency

 -  Vulnerable person or unable to provide informed consent

 -  Emergency

 -  Person unable to comply with required study follow up

 -  Contraindication to the study procedure